Abstract: The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.
Type:
Application
Filed:
May 11, 2018
Publication date:
September 13, 2018
Inventors:
Siva N. Raman, Jae Han Park, Thomas A. Diezi, Clifford J. Herman, Sunil K. Battu, Eric A. Burge
Abstract: A topical composition for treating an inflammatory skin disease in a subject includes a therapeutically effective amount of a biguanidine, and is in a dosage form for topical administration. A method for treating an inflammatory skin disease in a subject includes the following steps: identifying a subject in need thereof; providing a biguanidine; and administering the biguanidine in a therapeutically effective amount to a part of the subject to treat the inflammatory skin disease.
Type:
Application
Filed:
March 9, 2018
Publication date:
September 13, 2018
Inventors:
Beyong Deog PARK, Se Kyoo JEONG, Kyung Ho PARK, Kyong Oh SHIN, Hyun Jong KIM
Abstract: It has been demanded to develop a formulation for a novel external preparation having excellent transdermal absorption of a basic pharmacologically active component contained therein. It is found that the lipid solubility (log P values) of a basic pharmacologically active component and an organic acid (particularly a fatty acid) contribute significantly to the transdermal absorption of the basic pharmacologically active component in the selection of proper combinations of the basic pharmacologically active component and the organic acid. Namely, it is found that superior transdermal absorption of a basic pharmacologically active component having a lipid solubility level of 0.5 to 5 can be achieved by forming a salt of the component with a fatty acid having a lipid solubility level of ?1 to 4. Thus, it becomes possible to provide a novel external preparation having excellent transdermal absorption properties.
Abstract: The present invention relates to an injectable pre-formulation comprising a low viscosity mixture of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one oxygen containing organic solvent; d) at least one 5HT3 antagonist; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. Such compositions may additionally comprise polar solvents and/or further active agents such as opioid agonists and/or antagonists. Methods of treatment, particularly for management of nausea and vomiting such as for post-operative nausea and vomiting and/or therapy induced nausea and vomiting are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.
Type:
Application
Filed:
September 16, 2016
Publication date:
September 13, 2018
Applicants:
Camurus AB, Camurus AB
Inventors:
Fredrik Tiberg, Markus Johnsson, Justas Barauskas
Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
Type:
Application
Filed:
May 11, 2018
Publication date:
September 13, 2018
Inventors:
Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
Abstract: The present invention relates to methods of forming miniemulsions and use of the miniemulsions as a delivery system for bioactive agents. In particular, the present invention relates to methods for forming a miniemulsion comprising providing a first phase comprising a hydrophilic surfactant, lipophillic surfactant and water and a second phase comprising a lipid, wherein said miniemulsion comprises emulsified particles having a mean diameter of 1 ?m or less.
Abstract: Disclosed are a method of preparing liposomes using a mixed solvent of ethyl acetate and n-hexane for dissolving phospholipids, and a method of preparing a liposome frozen powder by putting a container including liposomes in a container filled with isopropyl alcohol, ethanol and/or methanol, followed by lyophilization, which methods are useful in food industry for no use of toxic chloroform. Disclosed also is adding the produced container including liposomes to a container filled with isopropyl alcohol, ethanol and/or methanol, followed by lyophilization, thus advantageously preventing deterioration in stability of liposome particles, as well as being almost completely returned to the original state.
Type:
Application
Filed:
September 13, 2016
Publication date:
September 13, 2018
Applicant:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Pahn Shick CHANG, Kyung Min PARK, Eun Hye YANG, Ho Sup JUNG
Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.
Abstract: The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.
Type:
Application
Filed:
May 14, 2018
Publication date:
September 13, 2018
Inventors:
Marta VIVANCOS MARTINEZ, Lisardo ALVAREZ FERNANDEZ, Jose VELADA CALZADA
Abstract: Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising a Nav1.7 selective inhibitor and a biodegradable carrier, wherein the agent is incorporated within the biodegradable carrier. Methods of treating pain in a subject and kits for producing compositions for treating acute, chronic or post-operative pain in in a subject are also disclosed herein.
Type:
Application
Filed:
March 8, 2018
Publication date:
September 13, 2018
Inventors:
Francis M. Reynolds, Jason M. Criscione, Robert Samuel Langer, Dana Tilley, Haining Dai
Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.
Type:
Application
Filed:
May 10, 2018
Publication date:
September 13, 2018
Applicant:
UNIVERSITY OF ROCHESTER
Inventors:
John Elfar, Kuang-Ching Tseng, Mark Noble
Abstract: Encapsulated probiotic compositions that deliver a minimum of 5 Billion CFU/capsule in potency and a minimum of at least 1 probiotic strain with clinical efficacy throughout shelf life are disclosed herein. In some embodiments, the encapsulated probiotic compositions meet the USDA certified organic labeling requirement, including 5% or less of non-organic materials.
Type:
Application
Filed:
March 9, 2018
Publication date:
September 13, 2018
Inventors:
William Robert King, Vidya Ananth, John Eleftheriou Theofanous, Gregory Thomas Horn, Maha Y. El-Sayed
Abstract: Publicly available pullulan hard capsule shells present certain drawbacks, notably a non fully satisfactory shell mechanical strength (i.e. shell brittleness) at shell low LOD. Improving this property is a particularly desirable goal for pullulan hard capsule shells. The present invention solves this and other objects by providing new hard pullulan capsule shells and capsules comprising (I) moisture, (II) a mono-, di-, and oligosaccharides free pullulan and (III) a setting system. Also provided are an aqueous composition and a dip-molding manufacturing method for the manufacture of such shells and capsules.
Type:
Application
Filed:
May 10, 2018
Publication date:
September 13, 2018
Applicant:
Capsugel Belgium NV
Inventors:
Dominique Nicolas Cade, Takahisa Takubo
Abstract: Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant.
Type:
Application
Filed:
May 9, 2018
Publication date:
September 13, 2018
Inventors:
James A. Helliwell, Amanda M. Malone, Thomas J. Smith, Marc M. Baum
Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
Type:
Application
Filed:
May 10, 2018
Publication date:
September 13, 2018
Inventors:
Alexey Popov, Elizabeth M. Enlow, James Bourassa, Colin R. Gardner, Hongming Chen, Laura M. Ensign, Samuel K. Lai, Tao Yu, Justin Hanes, Ming Yang
Abstract: The present invention relates to methods for treating systemic inflammation. In certain embodiments, the method comprises administering a therapeutically effective amount of curcumin-selenium loaded nanoparticles. The curcumin-selenium loaded nanoparticles can comprise a matrix of chitosan, polyethylene glycol and tetramethoxysilane encapsulating curcumin and selenium. In certain embodiments, the method comprises administering a therapeutically effective amount of nitric oxide-releasing nanoparticles. The nitric oxide-releasing nanoparticles can comprise a matrix of chitosan encapsulating nitric oxide. In certain embodiments, the systemic inflammation can be caused by endotoxemia. In certain embodiments, the systemic inflammation can be caused by a Filovirus, including an Ebola virus or a Marburg virus. In certain embodiments, the methods for treating systemic inflammation in a subject result in the reduction of proinflammatory cytokines in a subject.
Type:
Application
Filed:
November 3, 2015
Publication date:
September 13, 2018
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., UNIVERSITY OF CALIFORNIA SAN DIEGO
Inventors:
Joel M. Friedman, Mahantesh Navati, Adam J. Friedman, Pedro Cabrales
Abstract: The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating psychiatric disorders.
Abstract: The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating neuropsychiatric diseases and disorders.
Abstract: The present disclosure relates to a method for manufacturing a device for herbal medicine in which the airborne release of medicinal ingredients can be controlled, which comprises: separating two or more medicinal herbal ingredients prescribed or prepared according to pharmacological effects on the basis of the weight ratio of each medicinal ingredient to total weight of the medicinal ingredients; grinding the medicinal ingredients separated on the basis of weight ratio, wherein fine particles are ground to different sizes according to the setting of release duration; preparing herbal medicine by mixing the ground medicinal ingredients together, and then mixing the ingredients with a binding agent; and adhering the herbal medicine to a base sheet.
Abstract: This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.
Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
Abstract: In various embodiments, the present invention is directed to oral pharmaceutical compositions. For example, in some embodiments, the present invention is directed to taste-masked compositions. In some embodiments, the taste masked compositions comprise a highly water soluble drug such as amphetamine, e.g., in the form of a salt such as amphetamine sulfate. In various embodiments, the present invention is directed to taste-masked, orally disintegrating compositions.
Abstract: Aqueous, topical antifungal compositions contain an allylamine or an azole as the antifungal agent together with a lactate ester, an organic acid (pKa 3.8-5), a C2 to C6 saturated aliphatic alcohol, and a cationic galactomannan gum.
Type:
Application
Filed:
October 7, 2016
Publication date:
September 13, 2018
Inventors:
Servet Buyuktimkin, Nadir Buyuktimkin, James L. Yeager
Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
Abstract: The present invention relates to a composition for preventing or treating mitochondrial diseases caused by immunosuppressants, and immune diseases, containing metformin and, more specifically, to a composition for treating mitochondrial diseases caused by immunosuppressants, containing metformin; a pharmaceutical composition for preventing or treating immune diseases, containing, as active ingredients, metformin and an immunosuppressant, which is a target of rapamycin inhibitor (mTOR inhibitor); and a pharmaceutical composite formulation for preventing or treating immune diseases, containing, as ingredients, metformin and a mammalian target of rapamycin inhibitor, wherein the metformin and mammalian target of rapamycin inhibitor are administered simultaneously or separately, or administered in a predetermined sequence.
Type:
Application
Filed:
February 23, 2018
Publication date:
September 13, 2018
Inventors:
Mi La Cho, Chul Woo Yang, Sung Hwan Park, Seon Yeong Lee, Min Jung Park, Joo Yeon Jhun, Sun Woo Lim, Byung Ha Chung, Eun Kyung Kim, Jae Kyung Kim, Hyun-Sik Na, Se-Young Kim, Eun Jung Lee, Hyeon-Beom Seo
Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
Type:
Application
Filed:
May 10, 2018
Publication date:
September 13, 2018
Inventors:
Sung Wuk KIM, Sung Soo JUN, Chang Hee MIN, Young Woong KIM, Min Seok KANG, Byung Kyu OH, Se Hwan PARK, Yong Eun KIM, Duck KIM, Ji Sun LEE, Ju Hoon OH
Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Type:
Application
Filed:
May 14, 2018
Publication date:
September 13, 2018
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Type:
Application
Filed:
May 15, 2018
Publication date:
September 13, 2018
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract: Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
Type:
Application
Filed:
May 14, 2018
Publication date:
September 13, 2018
Inventors:
Mike Allan Royal, James Bradley Breitmeyer
Abstract: Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
Type:
Application
Filed:
December 12, 2017
Publication date:
September 13, 2018
Inventors:
Gary Hammer, Tom Kerppola, Raili Kerppola
Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck-pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid and has a pH below 4. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.
Type:
Application
Filed:
May 9, 2018
Publication date:
September 13, 2018
Applicant:
Glykon Technologies Group, LLC
Inventors:
Dallas L. CLOUATRE, Daniel E. CLOUATRE, Brad J. DOUGLASS
Abstract: Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein.
Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
Abstract: The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF). More specifically, the present invention relates to a pharmaceutical composition for oral use in treating psoriasis by administering a low daily dosage in the range of 375 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.
Type:
Application
Filed:
May 15, 2018
Publication date:
September 13, 2018
Inventors:
Christin GALETZKA, Chris RUNDFELDT, Roland RUPP, Peder M. ANDERSEN
Abstract: The concentrated liquid diet disclosed is a concentrated liquid diet having a total amount of a medium-chain fatty acid having 8 carbon atoms and a medium-chain fatty acid having 10 carbon atoms included as constitutive fatty acids of a triglyceride being 2.5 to 8.0 g per 100 kcal of the energy of the concentrated liquid diet, the concentrated liquid diet having in the total mass of the medium-chain fatty acid having 8 carbon atoms and the medium-chain fatty acid having 10 carbon atoms the rate of the medium-chain fatty acid having 10 carbon atoms being no less than 60% by mass, and the rate of the medium-chain fatty acid having 8 carbon atoms being no greater than 40% by mass.
Abstract: An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.
Abstract: The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.
Type:
Application
Filed:
March 5, 2018
Publication date:
September 13, 2018
Inventors:
Luigi Schioppi, Brian Talmadge Dorsey, Michael Skinner, John Carter, Robert Mansbach, Philip Jochelson, Roberta L. Rogowski, Cara Baron Casseday, Meredith Perry, Bryan Knox
Abstract: Compositions and methods of treating depression infections are provided. More particularly, compositions including a combination of ketamine and a cytochrome p450 enzyme inhibitor are provided. Methods of using the compositions for treatment of depression, including treatment-resistant or treatment-refractory depression, are provided. Compositions and methods of treating depression infections are provided. More particularly, compositions including a combination of ketamine and a cytochrome p450 enzyme inhibitor are provided. Methods of using the compositions for treatment of depression, including treatment-resistant or treatment-refractory depression, are provided.
Abstract: Mitigation of long and short-term detrimental effects of exposure to low dose ionizing radiation by administration of genistein in the form of a nanosuspension to a mammal in an amount effective for achieving genistein serum levels of between 1-5 ?M in the mammal throughout a time period from exposure to the ionizing radiation to twelve hours after exposure to the ionizing radiation.
Abstract: Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed. Methods for improving the development of the visual processing, visual acuity, or both, of an infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed.
Type:
Application
Filed:
May 11, 2018
Publication date:
September 13, 2018
Applicant:
ABBOTT LABORATORIES
Inventors:
MATTHEW KUCHAN, CHRON-SI LAI, JACQUELINE BOFF
Abstract: The PKC activator bryostatin-1 and its analogs increase the survival of dermal fibroblast cells. Bryostatin and picolog, a synthetic analog, are used as candidate therapeutic agents for improving the appearance of aging skin, reducing scar tissue formation, and improving the acceptance of a clinical skin grafts.
Abstract: The invention provides a compound of formula (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; or a salt thereof; for use in the treatment and/or prophylaxis of a condition, disease or disorder in a subject, wherein the compound or salt is orally administered to a subject in a daily amount of from 1.7 to 2.7 mmol per day, over a period of at least 21 days. Also are provided are the compound of formula (I) for use in increasing mitophagy and/or autophagy, maintaining and/or improving muscle function and administration as a dietary, nutritional and/or health supplement.
Type:
Application
Filed:
March 8, 2018
Publication date:
September 13, 2018
Inventors:
Christopher Rinsch, Penelope Andreux, Anurag Singh
Abstract: The invention provides a compound of formula (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; or a salt thereof; for use in the treatment and/or prophylaxis of a condition, disease or disorder in a subject, wherein the compound or salt is orally administered to a subject in a daily amount of from 2.8 to 6.6 mmol per day, over a period of at least 21 days. Also are provided are the compound of formula (I) for use in increasing mitophagy and/or autophagy, maintaining and/or improving muscle function and administration as a dietary, nutritional and/or health supplement.
Type:
Application
Filed:
March 8, 2018
Publication date:
September 13, 2018
Inventors:
Christopher Rinsch, Penelope Andreux, Anurag Singh
Abstract: The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.
Type:
Application
Filed:
September 8, 2016
Publication date:
September 13, 2018
Inventors:
Philippe DIOLEZ, Dominique DETAILLE, Frédéric MARIN, Olivier PETITJEAN
Abstract: This invention provides ex vivo methods for making modified PBMC compositions having overall anti-fugetactic properties for the effective and efficient treatment of tumors or cancers in a patient, and compositions and use thereof, following treatment with an antigen presenting cell-based vaccine against a cancer antigen.
Abstract: The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.
Type:
Application
Filed:
October 13, 2017
Publication date:
September 13, 2018
Inventors:
Anthony Alexander McKinney, Frank Bymaster, Walter Piskorski